Scaling up the bioproduction process of an in-ovo nanovaccine to protect broilers against avian colibacillosis in poultry farms in low- and middle-inc

About this project

Avian colibacillosis is one of the most prevalent diseases in the poultry industry, particularly in tropical areas like Brazil, resulting in high rates of morbidity and mortality on poultry farms and leading to substantial economic losses, negative impacts on animal welfare, and risks to human health. With the global consumption of chicken meat rising, poultry production has been pushed to intensive practices, mainly in low- and middle-income countries where this industry is in great expansion. This growth increases the level of risk, but the only available vaccine in the veterinary market against avian colibacillosis has a low efficacy rate of 30%-40%. Moreover, its use in chicks has potential hazards and risks of persistent contamination. The use of antimicrobials is a widespread alternative for disease management in poultry operations, but this is raising concerns about antimicrobial resistance. The use of bio-based nanoparticles has been widely explored in vaccinology to increase the safety and efficacy of vaccines. More than 15 years of development and optimization of nanovaccines has resulted in a candidate that demonstrates an 80% efficacy rate in protecting chicks from avian colibacillosis. This project is supporting the optimized production and clinical effectiveness of this nanovaccine by producing the first industrial vaccine batch and testing the in-vivo safety, immunogenicity and effective protection in chicks. The research team is working closely with poultry p…

Published by

International Development Research Centre · Other public sector

Countries

Brazil

Sectors

Agricultural research

Published by International Development Research Centre to the International Aid Transparency Initiative (IATI), last updated 1 Sept 2026 and imported automatically. IATI identifier: XM-DAC-301-2-110301-002.

No updates yet.